Replies to post #65616 on Biotech Values

[DewDiligence]

MNTA ReadMeFirst

[Updates:
Status of possible Lovenox patent rehearing;
Copaxone data in CIS;
revised insider shareholdings;
anticoagulant index;
table of recent biotech buyouts.]


**NOTE: The standstill agreement between
Novartis and Momenta expired on 25-Jul-2008**


What is MNTA’s business all about?
#msg-31026200 Edited transcript from 2Q08 CC
#msg-28748329 MNTA helps FDA with contaminated heparin
#msg-30941510 2008-2009 news flow
#msg-25377212 Standstill agreement with NVS expired on 7/25/08
#msg-25473104 Capsule explanation of proprietary technology
#msg-19626947 Sugars, peptides and glycoproteins, in that order
#msg-24624700 Apropos to above (2005 PR)
#msg-28865474 Characterizing a compound by “ruling out” structures
#msg-29053373 Odds and ends from 5/5/08 DB webcast


Valuation and finances
#msg-30936204 2Q08 financial results
#msg-31026200 Edited transcript from 2Q08 CC
#msg-29008722 Musings on valuation
#msg-32327350 Recent biotech buyouts at a large premium


Management and BoD
#msg-12824293 Craig Wheeler hired from Chiron
#msg-29957474 Composition of Board of Directors
#msg-32185823 Insider shareholdings
#msg-28899840 Largest shareholders
#msg-27338039 James Roach appointed CMO


Generic-Lovenox program
#msg-29282120 Sanofi’s US Lovenox patent invalidated
#msg-31805216 Court to rule on rehearing (180-day clock)
#msg-28896384 MNTA to resubmit ANDA in 3Q08
#msg-12222305 2006 partnership with Sandoz
#msg-25534402 Economics of the Lovenox partnership (1)
#msg-29462063 Economics of the Lovenox partnership (2)
#msg-12685766 Royalties payable to MIT
#msg-31106676 Lovenox sells $4.0B per year
#msg-28934793 Largest-selling generic of all time?
#msg-28936334 Where do Lovenox sales come from?
#msg-26739674 Lovenox US market share
#msg-28900092 FDA action on Teva/Amphastar ANDA’s?
#msg-29728035 How generic Rx’s are written in Europe
#msg-29698599 Competition from new oral anticoagulants


M118 (proprietary anticoagulant) program
#msg-26897124 “Checklist” rationale for M118 program
#msg-26900300 M118 has blockbuster potential
#msg-30966320 Revised M118 timeline from 2Q08 CC
#msg-29698599 M118 vs new oral anticoagulants
#msg-27272430 Meeting an unmet need
#msg-26898084 How M118 binds both FIIa and FXa (graphic)
#msg-31058135 M118 clinical trials
#msg-31029674 Musings on lack of drug interactions


Generic-Copaxone program
#msg-30621490 FDA accepts Copaxone ANDA for review
#msg-30938608 MNTA/Sandoz have first-filer status
#msg-30958852 Craig Wheeler’s comments on Teva’s patents
#msg-30960930 List of Copaxone patents being challenged
#msg-30649453 Notes from 7/11/08 Copaxone conference call
#msg-26893858 Musings on upside of Copaxone program
#msg-30647865 “Controlled Chaos” (reverse engineering)
#msg-12222305 Copaxone falls under 2006 NVS collaboration
#msg-31043795 Copaxone sales keep growing
#msg-31152081 Copaxone is world’s biggest MS drug
#msg-32316091 Copaxone data in CIS
#msg-31249570 Tysabri forecasts unrealistic, analysts say
#msg-29902618 Mylan enters the fray—sort of.
#msg-30498483 Teva’s trial with 40mg dose fails
#msg-31515145 FTY720 setback (Nature Biotechnology)
#msg-31519342 MS drugs in phase-2 or phase-3


Follow-on Biologics (FoB) programs
#msg-27114485 US FoB’s are a question of when not if
#msg-26837144 Salient FoB quote from MNTA’s CEO
#msg-12222305 2006 FoB partnership with Sandoz
#msg-25514154 Speculation on the FoB’s to be developed (ThomasS)


Competition
#msg-32171984 Anticoagulant index
#msg-29698599 Competition from new oral anticoagulants


Feature stories on MNTA and related topics
#msg-27286206 Boston Globe (3/08)
#msg-25160571 WSJ (12/07)
#msg-25933221 Bioworld (11/07)
#msg-23005127 Nature (9/07)
#msg-20308884 Lab Technologist (6/07)
#msg-25803923 The Pink Sheet (3/07)
#msg-13119848 Chemical & Engineering News (9/06)
#msg-12686142 Boston Globe (8/06)
#msg-7370282 WSJ (8/05)
#msg-25779774 Boston Globe (11/04)